×

Neville Registrars is delighted to welcome Stilo International Limited as the newest addition to its list of client companies.

Stilo International provides tools to help organizations to automate the conversion of content to XML, author new content in XML format (particularly those with no knowledge of XML), and to build XML content processing components integral to enterprise-level publishing solutions.

Operating from offices in the UK and Canada, the Company supports commercial publishers, technology companies and government agencies around the world by providing exceptional tools to help implement structured content solutions.

Further information can be found on the Company's website: https://www.stilo.com/

 

 

Close

×

RNS Number : 2579D

Crimson Tide PLC

18 February 2020

 

Crimson Tide Plc

Significant contract wins in the rail sector

 

Crimson Tide Plc (TIDE) announces a series of major contract awards with the rail sector totalling in excess of £600,000 of long term contracted revenue.

Two major Network Rail managed stations in London have invested in mpro5 to not only remove the vast amount of paper from the station operations but also ensure that remedial actions raised from auditing or incidents are digitized automatically and followed through to conclusion via defined workflows.  

Following a highly successful first year of operation in the train presentation area, we are delighted to announce that Chiltern Railways, having experienced the value and benefits in their business have extended and expanded the subscription to cover safety, procurement, human resources, revenue protection, security and engineering departments resulting in a significant increase in monthly subscriptions.

Having worked with the innovation team and our partner Samsung throughout 2019, MTR Elizabeth Line have chosen to invest in mpro5 as their strategic workflow tool of choice. Initially deployed in some high priority departments and activities totally without digitization tools, the ambition over the next twelve months is to deploy across further staff replacing legacy, outdated or less functionally rich applications to make mpro5 the default workflow tool.

Barrie Whipp, Executive Chairman commented: "Within eighteen months of entering a sector, we are contracted to, or in discussions with, the majority of major players in the rail business in the UK. Our team has embraced the industry, learnt from some fantastic partners and are delivering real value day in, day out. mpro5 has a very real opportunity of becoming an industry standard tool, and from the feedback we are getting from our clients, it should be".  

 

For further information:

 

Crimson Tide plc

Barrie Whipp / Luke Jeffrey                                                                        01892 542 444

 

Arden Partners

John Llewellyn-Lloyd / Dan Gee-Summons                                              020 7614 5900

 

For further information on Crimson Tide plc, see the website at: www.crimsontide.co.uk/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTTRMATMTIBBRM

Close

×

RNS Number : 1121D

First Derivatives PLC

17 February 2020

 

17 February 2020

 

First Derivatives plc

("FD" or the "Group")

 

Major oilfield services contract win

 

FD (AIM: FDP.L, ESM: FDP.I) announces that it has been selected by a leading global oilfield services company for the use of Kx technology to provide operational intelligence for their customers' oil and gas field assets. This contract, awarded after a thorough technology evaluation by the client, extends the range of Kx use cases within the energy market and showcases the ability of Kx to deliver actionable insights at the edge.

 

 

The flexibility and open nature of the Kx platform will enable new processes and data-intensive analytics to be added as required both in the field and centrally.

 

Using Kx technology to deliver big data levels of analytic capability to the edge, where compute resources are limited, will enable the client to increase efficiency. This represents a new use case for Kx, which the client expects to generate a high return on investment and should be of interest across the broader energy and industrial IoT markets.

 

Seamus Keating, Chief Executive Officer, FD commented: "Making decisions at the time and place where action is required can deliver major operational efficiencies. We believe Kx is the only technology capable of delivering this solution, enabling decision-making in real-time on vast volumes of data. As organisations increasingly look to drive action, not just reports from the data they generate, Kx stands out for its high performance and ability to operate at the edge."

 

 

Enquiries

For further information please contact:

 

First Derivatives plc Seamus Keating, Chief Executive Officer Graham Ferguson, Chief Financial Officer Ian Mitchell, Head of Investor Relations	+44(0)28 3025 2242 www.firstderivatives.com
Investec Bank plc (Nominated Adviser and Broker) Andrew Pinder Carlton Nelson Sebastian Lawrence	+44 (0)20 7597 5970
Goodbody (Euronext Growth Adviser and Broker) David Kearney Don Harrington Finbarr Griffin	+353 1 667 0420
FTI Consulting Matt Dixon Dwight Burden Darius Alexander	+44 (0)20 3727 1000

About FD

FD is a global technology provider with more than 20 years of experience working with some of the world's largest finance, technology, automotive, utility, manufacturing and energy institutions. The Group's Kx technology, incorporating the kdb+ time-series database, is a leader in high-performance, in-memory computing, streaming analytics and operational intelligence. Kx delivers the best possible performance and flexibility for high-volume, data-intensive analytics and applications across multiple industries. FD operates from 15 offices across Europe, North America and Asia Pacific, including its headquarters in Newry, and employs more than 2,400 people worldwide.

 

For further information, please visit www.firstderivatives.com and www.kx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTFLFIRFIISLII

Close

×

Neville Registrars is delighted to welcome Progility Limited as the newest addition to its list of client companies.

Progility provides professional business solutions to global organisations and consumers in order to develop the best project management eco-system possible

Further information can be found on the Company's website: https://www.progility.com/

Close

×

Neville Registrars is delighted to welcome Seagray Group Limited as the newest addition to its list of client companies.

 

Close

×

RNS Number : 6622B

Pennant International Group PLC

03 February 2020

 

                                                                                                                                                           

FOR IMMEDIATE RELEASE                                                                                          3 February 2020          

PENNANT INTERNATIONAL GROUP PLC

 

Contract Wins

 

Pennant International Group plc ("Pennant", the "Group", or the "Company"), the AIM quoted supplier of integrated training and support solutions, products and services which train and assist operators and maintainers in the defence and regulated civilian sectors, is pleased to announce that it has been awarded two new contracts.

 

Australia

 

Pennant Australasia Pty Ltd (the Group's wholly-owned Australian subsidiary) has been awarded a contract for the supply of Pennant training aids and associated services for aviation technician training for the Australian Defence Force at a new training facility in Nowra, Australia.

 

The contract has been awarded by Air Affairs Australia Pty Limited, and is Pennant's second contract in region for training aids. The support services element forms part of the Group's long term strategy to generate an increasing proportion of its revenues from services, particularly services which are both complementary to its product range and relevant to the sectors within which it already operates.

 

The contract is to be delivered over 2020 and 2021 (as an initial phase). The contract value is commercially confidential.

 

Middle East

 

Just prior to year-end, the Group received an order valued at circa £1.5 million for the provision of additional training aids to the Middle East. The order includes two new training solutions, including a 'crew escape trainer', which have been created under the Group's product development strategy and will form part of the Group's range of generic training aids.

 

The contract is 'engineered-to-order' and the majority of revenues will be recognised in 2020 (being supportive of current market expectations).

 

The Group anticipates receiving further orders from this long-standing customer during the year.

 

 

 

Phil Walker (Group CEO) commented: "These exciting new contracts demonstrate not only the increasing diversity of our product and services portfolios but also the Group's continued ability to win business internationally. They will also help to underpin the Group's 2020 financial performance."

 

 

Enquiries:

 

Pennant International Group plc	www.pennantplc.co.uk
Philip Walker, CEO David Clements, Commercial & Risk Director	+44 (0) 1452 714 914
WH Ireland Limited (Nomad and Broker)	www.whirelandcb.com
Mike Coe Chris Savidge	+44 (0) 117 945 3470
Walbrook PR (Financial PR)	[email protected]
Paul Vann Tom Cooper	+44 (0)20 7933 8780 Mob: +44 (0)7768 807631

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTUUSARRNUURUR

Close

×

Neville Registrars are delighted to welcome Seagray Group Limited as the newest addition to its list of client companies.

Seagray Group develops, acquires and licences software and seeks opportunities to trade in markets utilising this technology.

Further information can be found on the Company’s website: https://seagray.com/

Close

×

RNS Number : 5499B

Sativa Group PLC

31 January 2020

 

Press Release

31st January 2020

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Sativa Group Plc

 

("Sativa" or "the Company" or "the Group")

 

Goodbody Botanicals signs deal with Alliance Healthcare

for product distribution to UK Pharmacies

 

Sativa Group Plc subsidiary Goodbody Botanicals has secured a product listing agreement with Alliance Healthcare ("Alliance"), one of the leading distributors and wholesalers of pharmaceutical, medical and healthcare products in the UK and Europe.  This gives Alliance's 10,000+ high street retailer customers access to the Goodbody Botanicals range of market-leading CBD products.  Alliance Healthcare services independent pharmacies, national accounts, and superstores. 

 

In addition, Alliance's syndicated pharmacy salesforce, Skills in Healthcare, has been contracted to promote and sell the Goodbody Botanicals range to the 1,500 top performing independent pharmacy customers.  

 

Sativa Chief Executive Henry Lees-Buckley said: "The Alliance distribution agreement is a significant step in Sativa's Goodbody Botanicals CBD Wellness brand's objective to grow market share with high street pharmacies, grocers, and superstores." 

 

Media enquiries. 

Abchurch Communications Julian Bosdet +44 (0)207 4594 4070  +44 (0) 7771 663 886

[email protected] www.abchurch-group.com

 

For further information please contact: 

 

Henry Lees-Buckley  Chief Executive Officer Sativa Group Plc  +44 (0) 20 7971 1255   [email protected] www.sativagroup.co.uk	Joseph Colliver Chief Financial Officer Sativa Group Plc  +44 (0) 20 7971 1255   [email protected]  www.sativagroup.co.uk
NEX Exchange Corporate Adviser   Corporate Finance  Stephen Keys / Max Gould  Cenkos Securities plc  +44 (0) 20 7397 8900	Equity Sales  Julian Morse Cenkos Securities +44 (0) 20 7397 8900

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NEXUARBRRWUAORR

Close

×

Neville Registrars is delighted to welcome Eco Hotels UK Plc as the newest addition to its list of client companies.

 

Eco Hotels is an owner, developer and asset manager of The Eco™ and The Ecolodge™, three star premium and two star value brands.

 

Further information can be found on the Company's website: https://ecohotelsglobal.com/

Close

×

RNS Number : 2156B

N4 Pharma PLC

29 January 2020

 

29 January 2020

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

Update on Nuvec® process improvements

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide an update on the progress of its work to improve the dispersion of Nuvec®, details of which were announced in the Company's Interim Results on 18 September 2019.

 

The first two stages of phase one of the in vitro work have now been completed. The Company has manufactured a new batch of Nuvec® using an improved process and has successfully demonstrated that the Nuvec® particle can be effectively and repeatedly dispersed into a more monodisperse formulation, prior to the addition of DNA. The Company expects that this more monodisperse formulation will result in a more even distribution of DNA across the Nuvec® nanoparticles, thereby resulting in a more monodisperse formulation of DNA loaded Nuvec®.

 

A number of techniques are available to measure particle size distribution, including dynamic light scattering, laser diffraction and transmission electron microscopy (TEM). The Company has compared these nanoparticle measurement techniques to ensure a full understanding of the extent of agglomeration of Nuvec®. N4 Pharma's analysis of these techniques has confirmed that TEM provides a robust assessment of the size and morphology of individual nanoparticles and that laser diffraction is a more suitable and consistent process to measure Nuvec® dispersion in an aqueous solution and to define the extent of agglomeration. Using TEM and laser diffraction the Company has been able to more accurately measure the size of individual nanoparticles and quantify the levels of dispersion seen for Nuvec®.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"The work highlighted in the Interim Results is moving forward well and we are pleased to have been able to produce a more disperse form of Nuvec® prior to the addition of DNA.

 

We will now move forward with the next stage of the work to investigate how to add DNA to this new more disperse Nuvec® in order to maintain this improved level of dispersion prior to injection.

 

We very much appreciate the support of our shareholders as we undertake this process improvement work and will provide further updates in due course."

 

Enquiries:

 

N4 Pharma Plc Nigel Theobald, CEO	Via Scott PR
Allenby Capital Limited James Reeve/Asha Chotai	Tel: +44(0)203 328 5656
Scott PR Georgia Smith	Tel: +44(0)1477 539 539

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

RESBPMRTMTJTBAM

Close